Here are four things to know:
1. The company sold 7.5 million shares at $12, surpassing its goal of $87.2 million. The final amount raised could reach more than $100 million.
2. It is the third Bay Area life sciences company to go public this year, after Audentes Therapeutics and Corvus Pharmaceuticals.
3. Though the company has raised $67 million since it was founded 15 years ago, it has no revenue. It has an accumulated deficit of $39.1 million.
4. Its primary stakeholders include Johnson & Johnson, Pharmstandard International and R.A. Capital Healthcare Fund.
More articles on gastroenterology and endoscopy:
Madrigal Pharmaceuticals names Dr. Richard Levy to board: 4 points
Finger Lakes Gastroenterology joins FLH Medical: 3 notes
HCSC, Florida Blue now cover Exact Sciences’ Cologuard: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.